Trials / Completed
CompletedNCT02388048
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in patients with lymphoblastic acute leukemia who have been already treated with other therapies.
Detailed description
This is a phase II multicenter, non-comparative, open label study for high risk previously treated patients with CLL, requiring therapy, aimed at evaluating the efficacy of the Ofatumumab and Ibrutinib combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib + ofatumumab |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2024-04-03
- Completion
- 2024-04-03
- First posted
- 2015-03-13
- Last updated
- 2025-01-29
Locations
35 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02388048. Inclusion in this directory is not an endorsement.